 Shares of Neuronetics Inc. STIM, -6.67 gained 22.5 in premarket trading on Tuesday after the company said it received clearance from the Food and Drug Administration to market its transcranial magnetic stimulation system as a treatment for anxiety in adults with major depressive disorder. The system was previously cleared to treat obsessive-compulsive disorder. 